FDA-APPROVED DOSE AND SCHEDULE
Metastatic Pancreatic Cancer (mPC)
Metastatic Pancreatic Cancer (mPC)


ILLUSTRATIVE PURPOSES ONLY
- Administer ABRAXANEfollowed by gemcitabine weeklyfor 3 weeks, then 1 week breakof each 28-day cycle
- ABRAXANE is administered intravenously over 30-40 minutes
- ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
- Administer ABRAXANE followed by gemcitabine weekly for 3 weeks, then 1 week break of each 28-day cycle
- ABRAXANE is administered intravenously over 30-40 minutes
- ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
Metastatic Breast Cancer (MBC)
Metastatic Breast Cancer (MBC)


ILLUSTRATIVE PURPOSES ONLY
- Administer ABRAXANE once every 3 weeks
- ABRAXANE is administered intravenously over 30 minutes
- ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
Advanced Non–Small Cell Lung Cancer (NSCLC)
Advanced Non–Small Cell Lung Cancer (NSCLC)


ILLUSTRATIVE PURPOSES ONLY
- Administer ABRAXANE on Days 1, 8, and 15 of each 21-day cycle
- Administer carboplatin on Day 1 only of each 21-day cycle, beginning immediately after the completion of ABRAXANE administration
- ABRAXANE is administered intravenously over 30 minutes
- ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
- Administer ABRAXANE onDays 1, 8, and 15 of each21-day cycle
- Administer carboplatin onDay 1 only of each 21-day cycle, beginning immediatelyafter the completion ofABRAXANE administration
- ABRAXANE is administeredintravenously over 30 minutes
- ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.